Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology
Gilead’s tie-up with Google’s Verily will explore the immunological underpinnings of rheumatoid arthritis, lupus and GI disorders. Janssen acquires BeneVir and its oncolytic virus expertise, while United Therapeutics buys out SteadyMed.
You may also be interested in...
Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.
Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.
Yescarta is off to a strong launch, but with US FDA approval of Novartis' Kymriah in a similar indication it now it has a competing CAR-T product with a similar label. Gilead's HCV business declined as expected, but the HIV franchise had a worse Q1 than anticipated.